BioLineRx is a clinical-stage biopharmaceutical company focused on oncology.

The company's pipeline currently consists of BL-8040, a platform for multiple cancer and hematological indications; and AGI-134, a synthetic immunotherapy in development for solid tumors.The BioLineRx pipeline is generated by systematically identifying, validating, and in-licensing therapeutic candidates with advantages over current therapies or that address unmet medical needs.BioLineRx also works with Novartis on the codevelopment of selected Israel-sourced novel drug candidates and has recently signed a collaboration agreement with MSD (known as Merck in the United States and Canada) to run a phase-2a study in pancreatic cancer using a combination of BL-8040 and Merck's Keytruda.BioLineRx has received the FDA biological product designation for its novel cancer immunotherapy candidate AGI-134.

In January 2020, the company announced that the European Commission had granted orphan drug designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer.